CK2/ERK8-IN-1 (TMCB) is a dual inhibitor of casein kinase 2 (CK2) (Ki: 0.25 µM) and ERK8 (IC50s: 0.50 μM) with pro-apoptotic efficacy. CK2/ERK8-IN-1 also binds to PIM1, DYRK1A, and HIPK2 (Kis: 8.65 µM, 11.9 µM, and 15.25 µM).

CK2α-IN-1 is a selective non-ATP-competitive CK2α inhibitor with an IC50 of 7.0 µM and a Ki of 1.6 µM.CK2α-IN-1 exhibits potential anticancer activity and can be used in cancer research.

CK2 inhibitor

CK1-IN-3 is casein kinase 1 (CK1) inhibitor and can be used for research on the treatment or prevention of diseases associated with circadiantiazol rhythm, inflammation diseases.

CK1-IN-2 (compound Nr.4) is a potent inhibitor of CK1, exhibiting IC50 values of 123 nM for CK1a, 19.8 nM for CK1d, 26.8 nM for CK1e, and 74.3 nM for p38a [1].

CK1-IN-1 (PUN51207) is a casein kinase 1 (CK1) inhibitor. CK1-IN-1 has IC50s of 15 nM, 16 nM, 73 nM for CK1δ, and CK1ε, p38σ MAPK, respectively.

SGC-CK2-1 is an ATP-competitive chemical compound that acts as a highly potent and cell-active CK2 inhibitor. It demonstrates excellent selectivity towards both isoforms of human CK2, with IC50 values of 36 nM for CK2α and 16 nM for CK2α′ in the nanoBRET assay. Given its properties, SGC-CK2-1 is a suitable tool for the investigation of neurodegenerative diseases.

CK176 is a capsid targeted inhibitor of HIV-1 replication. CK176 shows an 11-fold improvement over I-XW-053 in blocking HIV-1 replication in primary human peripheral blood mononuclear cells (PBMCs).

BRD4/CK2-IN-1 is the first potent, orally active dual-target inhibitor of BRD4/CK2 (bromodomain-containing protein 4/casein kinase 2), acting on both BRD4 (IC50: 180 nM) and CK2 (IC50: 230 nM). In triple-negative breast cancer (TNBC), BRD4/CK2-IN-1 induces apoptosis and autophagy-related cell death.

Casein Kinase inhibitor A51 is an orally active casein kinase 1α (CK1α) inhibitor with anticancer activity that induces apoptosis in leukemia cells, and may be used in the study of neck cancers, acute myeloid leukemia, breast and prostate cancers.

1. Ilexsaponin A (Ilexsaponin A1) shows protective effects on ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway.

Z-FK-ck (Z-Phe-Lys-2,4,6-Trimethylbenzoyloxy-methylketone) serves as a potent, selective inhibitor of gingipain-K. This compound effectively extends plasma thrombin time (TT) proportionally with dosage and duration [1].

TDZD-8 (NP 01139) is an inhibitor of GSK-3β, with an IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.

Cosibelimab (CK-301; TG-1501) is a fully human, high-affinity monoclonal antibody that inhibits PD-L1 by preventing its interaction with PD-1. This compound, featuring a functional Fc domain, is effective in inducing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), targeting and eliminating PD-L1+ cell lines, such as lymphoma cells [1].

Olafertinib (RX-518) is a novel mutant-selective, irreversible, orally available EGFR inhibitor. It can overcome T790M-mediated resistance in NSCLC.

CK-119 is an interleukin-1 blocker, which mainly inhibits the growth of fibroblast-like corneal and conjunctival cells by inhibiting the synthesis of DNA and RNA.

CK-17 is an interleukin-1 antagonist and an IL-1 blocker, which inhibits fibroblast proliferation in a concentration-dependent manner.

CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1 (IC50s: 3.787 μM and 4.327 μM). It is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions.